Lonza and Touchlight collaboration to bring expanded end-to-end mRNA offerings
Key Insights and Signals – Hospital & Healthcare
Centre Setup MVP Health Care Fitness Court opens in the village of Phelps A ribbon-cutting ceremony was held earlier this month, opening the new MVP Health Care Fitness Court. The space was created with people 14 and older in mind. It is a free, open-air wellness center located just behind the Phelps Community Center. Read More>>Deals MSSU extends Sports Medicine Program contract with Freeman Health System Newstalk KZRG MSSUs Board has voted to extend its Sports Medicine Program contract with Joplin’s Freeman Health System for over a decade. The extended agreement agrees to maintain Freeman Health System as the exclusive provider of sports medicine and orthopedic care for MSSU athletics. Read More>>Merger and Acquisition GeneraLifes acquires Livio Group Livio is the largest fertility clinics group in the Nordics, present with 9 clinics in Sweden, Norway, and Iceland. The acquisition also encompasses Livio’s own gamete bank, Livio Egg and Sperm Bank, with a sales hub in Denmark. Read More>>Partnerships CHOP and Main Line Health to forge a new pediatric partnership Main Line Health is partnering with the Children’s Hospital of Philadelphia to deliver pediatric care at its suburban facilities. The agreement announced earlier this week ends its 25-year relationship with Nemours Children’s Health in Wilmington for pediatric services. Read More>> Hound Labs forms a strategic agreement with Quest Diagnostics The agreement establishes Quest as the exclusive provider of laboratory services for confirmatory testing of positive breath sample results generated by the Hound’s Cannabis Breathalyzer, used by employers on location as an objective measure to detect and deter cannabis use during the workday. Read More>>Executive Movement Lisa Powell joins MultiCare as the new senior VP and Chief Human Potential Officer Powell brings more than 20 years of health care human resources experience. Joining MultiCare brings Powell back to Tacoma, where she started her career as the human resources director for Community Health Care. Read More>> Trinity Health of New England names Dr. Montez Carter as the new CEO In his new role, Dr. Carter succeeds Reginald Eadie, MD, who will serve as senior vice president of physician enterprise development for Livonia. Dr. Carter will begin his new role on Oct. 3. Read More>> Sutter Health appoints Warner L. Thomas as the next CEO For the past ten years, Thomas has served as the president and CEO of Ochsner Health. In his new role, Thomas will succeed Conforti, Sutter Health’s COO, who has served as interim CEO since January 2022. Read More>>Financial and Market Activity HealthEquity reports second quarter financial results The company reported a net loss of USD 10.7 Mn, or USD 0.13 per diluted share, and a non-GAAP net income of USD 28.1 Mn, or USD 0.33 per diluted share, for the second quarter that ended Jul. 31, 2022. Read More>>Layoff Albany Med laying off dozens of workers The hospital has reported a USD 66 Mn year-to-date operating loss. The 37 positions that are being eliminated are mostly non-clinical, and frontline workers were not affected. The hospital also says several staff members are also being moved or restructured. Read More>> Beaumont, Spectrum Health cuts hundreds of jobs The move comes amid significant midyear losses at Beaumont Health in southeast Michigan and lower earnings at Spectrum Health West Michigan. The cuts will affect non-clinical, administrative positions. Read More>>
Key Insights and Signals in Medical Devices
Centre Setup and Expansion MilliporeSigma continues SU expansion with USD 131 Mn France investment The Molsheim facility will see an increased capacity for manufacturing MilliporeSigmas Mobius single-use assemblies and create 800 jobs. The site already hosts the management of single-use Hardware and Software, as well as the manufacturing of NovaSeptum (a single-use sampling system). Read More>>Deals Grifols in a 15-year deal with Canada for plasma-based medicines Spanish pharmaceutical company Grifols has struck a 15-year renewable collaboration agreement with Canada’s national blood authority to increase the supply of immunoglobulins (Ig) in the country. Under the agreement, Grifols, which uses blood plasma to make medicines, will work with Canadian Blood Services (CBS) to also source the plasma in Canada. Read More>> Neovii and Fosun Pharma enter into an exclusive agreement This collaboration positions Grafalon for sustained growth in China and advances the development of stem cell transplants and beyond, as in devastating auto-immune and other diseases. Read More>>Partnerships eBlu Solutions announces collaboration with Cardinal Health eBlu will collaborate with Cardinal Health to provide its benefit investigation and prior authorization workflow to the latter’s new suite of revenue cycle management solutions (RCM). The collaboration between eBlu Solutions and Cardinal Health will support specialty providers that Cardinal Health serves by offering eBlu Solutions innovative technology. Read More>> Lonza and Touchlight collaboration will expand customers’ access to DNA Through this collaboration, Lonza will have the ability to expand its end-to-end offering for mRNA manufacturing with an additional source of DNA raw material. This material comes from Touchlight’s doggybone DNA (dbDNA), making it easier for customers to get to the dbDNA technology. Read More>>Executive Movement Nordson Corporation appoints Milton Morris to Board of Directors Dr. Morris’s appointment brings the number of Nordson directors to nine, following the departure earlier this year of Arthur George, who served on Nordson’s board for ten years. Dr. Morris will serve on the board’s audit committee immediately upon appointment. Read More>> LivaNova Board names Brooke Story the new Director Story joins the LivaNova Board with more than 20 years of experience in the global medical technology industry. She currently serves as Worldwide President, Integrated Diagnostic Solutions at BD (Becton, Dickinson and Company), a position she assumed in April 2021. Read More>> Cue Health appoints David Tsay as Chief Medical Officer As Chief Medical Officer, Dr. Tsay will help define future Cue diagnostic products and services. Dr. Tsay will also lead engagement across various healthcare stakeholders, driving communication, collaboration, and ecosystem alignment to support Cue’s healthcare initiatives. Read More>>Financial and Market Activity Masimo releases Q3 2022 earnings The company provided earnings per share guidance of USD 0.85- USD 0.97 for the period, compared to the consensus earnings per share estimate of USD 1.13. The company issued revenue guidance of USD 515.00 Mn – USD 545.00 Mn, compared to the consensus revenue estimate of USD 553.16 Mn. Read More>> Pacira BioSciences reports preliminary net product sales of USD 59.1 Mn for August 2022 The company’s net product sales include EXPAREL, ZILRETTA, and the iovera system. To provide greater transparency, the company is reporting monthly intra-quarter unaudited net product sales for EXPAREL, ZILRETTA, and iovera until it has gained enough visibility around the impacts of COVID-19. Read More>>
Key Insights and Signals in Pharmaceutical
Centre Setup and Expansion Hovione expands its drug product offering with a new manufacturing line dedicated to continuous tableting A new state-of-the-art continuous manufacturing facility is now coming online at the Loures site in Portugal. Hovione has further strengthened its capabilities by establishing a highly experienced multi-disciplinary global team in continuous tableting and upgrading its labs with the tools needed to support the drug product lifecycle. Read More>> Catalent plans to spend USD 2.2 Mn to expand Singapore clinical supply facility The expansion will also see the addition of specialized secondary packaging capabilities for ULT products, enabling the site’s services to support packaging campaigns and increasing capabilities to handle biopharmaceuticals and advanced modalities, including mRNA-based vaccines and cell and gene therapies. Read More>>Deals Thermo Fisher’s PPD lands National Cancer Institute contract The PPD clinical research business will coordinate the resources and processes necessary to identify and maintain a platform for collecting and migrating electronic patient-reported outcomes (ePROs) and other patient-generated health data into NCI Multi-Center Organization (MCO) clinical trials supported by CTSU. Read More>> OncoResponse and Regeneron enter cancer therapy clinical supply agreement The deal will aid in analyzing the fully human monoclonal antibody of OncoResponse, OR2805, and Libtayo (cemiplimab) in advanced cancer patients. A Phase I clinical trial is underway to evaluate the safety, pharmacokinetics, and initial anti-cancer activity of OR2805 alone and anti-PD-1 therapy in advanced solid tumor patients. Read More>>Partnerships BriaCell partners with Caris Life Sciences to expand patient outreach and molecular profiling Under the terms of the agreement, Caris will help BriaCell with efficient patient identification, accelerating enrollment for its current Phase I/II clinical trial in advanced metastatic breast cancer of certain genetically defined subgroups. Read More>>Executive Movements ANI Pharmaceuticals appoints Krista Davis as Chief Human Resources Officer Ms. Davis brings over 20 years of executive leadership experience in human resources, talent management, and organizational development to the company. She previously served as a global Head of People & Organization for the Novartis Technical Operations Division, where she led P&O for the Global Cell & Gene platforms, supporting growth and the organization’s strategic transformation. Read More>> Bridgewater pharma firm appoints former Sanofi leader as EVP, Chief Commercial Officer Pesquin joins the company from Sanofi, where he served in leadership roles of increasing responsibility over his 11-year tenure, including most recently as North America head for general medicines. Read More>>Financial and Market Activity Bulgarian drug maker Sopharma’s net profit grows in H1 Sopharma has reported that its net profit rose to 43.4 Mn levs (USD 22.01 Mn) in the first half of 2022 from 32.2 Mn levs (USD 16.5 Mn) a year earlier. Growth was driven by higher revenue and a decrease in financial costs, the company said in an interim financial statement. Read More>>Layoff Bristol Myers, AbbVie plan to cut up to 360 California jobs The company plans to cut up to 261 jobs in two different locations in San Diego. The job cuts follow the company’s USD 4.1 Bn acquisition of drug developer Turning Point Therapeutics, which closed in August. Separately, AbbVie plans to cut up to 99 jobs in Irvine. Read More>>
Did you find the newsletter helpful? *|SURVEY: Yes|* *|SURVEY: No|*
Latest Industry Insights from Draup Braindesk
Draup analyzed the biotech platforms of Johnson & Johnson Services for manufacturing pharmaceutical products & services.
The analysis was conducted through the lens of 4 areas. The clusters considered are as follows: 1. Drugs Development
4. Data Science
In November 2021, Johnson & Johnson decided to split its consumer health business into Johnson & Johnson and a New consumer health company, which will complete within 18-20 months. Joaquin Duato, the CEO, will lead the new Johnson & Johnson company after the separation. In the future, Paul Ruh will appoint as Chief Financial Officer of a New consumer health company.
The revenue value increased majorly in the pharmaceutical segment, and the Europe region dominates the maximum financial growth of Johnson & Johnson. They focus on Telemedicine, wearable devices, and other tools to provide easy access to a range of digital mental health solutions.
Johnson & Johnson opened satellites and hub centers:
1. First Satellite Center for Global Health Discovery in Asia Pacific-new solution to address flaviviruses.
2. Innovation hub for smart health devices and mobile wellness management provides 30 brand-new healthcare startups.
3. Satellite Center to drive new solutions to address the current and rising threat of antimicrobial resistance.
Johnson & Johnson will focus on the following areas in the future:
1. Develop preventive viral vaccines and health security threats.
2. Develop new treatments to address global health priorities, mainly TB treatments.
3. For the past ten years, Johnson & Johnson has invested $250 Million in strengthening the health system.
Company – Kinside Total Funding– USD 16.62 Mn About: Kinside is a comprehensive platform for working parents to find, secure, and save on child care. The platform partners with child care providers to offer exclusive tuition discounts and work with dependent care FSA accounts for accessible, affordable payment options. Read More>>
Latest Reports Published in Draup
DentaQuest Account Intelligence Report
DentaQuest focuses on developing Oral Healthcare and dental managed care, especially for kids, to prevent patients and get more positive outcomes. Read More>>
Here’s what’s new on our Sales Intelligence Platform Introducing KPIs specific to each use case in Industry Curator
Get to see your subscription-related information, including start and end date, under Administration
You can add list specific notes for a lead in Buyers
Introducing KPIs specific to each use case in Industry Curator